Mindset Pharma's strategy has a long term orientation that is predicated on a nuanced view of the future development of the medical psychedelic market. This long term, scientific focus requires the right investor. Negev Capital has surpassed all of our expectations as a capital partner; they did the work to not only understand our programs but to contribute to their direction through an ongoing collaborative dialogue that has benefited Mindset significantly. Since they got involved, they've also been there to support Mindset through the volatility of the public markets, investing capital at multiple junctures and offering strategic counsel. They are a true partner, not just an investor.

Portfolio Case Study

Negev Capital have been brilliant partners for Beckley Psytech. They have been extremely approachable and have a real understanding of the choices facing our management team, always providing very useful advice and insights about the broader market as well as the specifics of our business. They have great domain expertise and are really there to help us succeed.

Cosmo Feilding Mellen

Director and CEO

CEO, Mindset Pharma

James Lanthier

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

Negev Capital's investment has offered significant value to Filament Health. In addition to funding our core business, the team at Negev has broad sector expertise which is relevant to our strategic decisions. We have also benefited from Negev's relationships and introductions to other funds, counterparties, and contractors participating in the psychedelic industry.

Portfolio Case Study

Negev helps management with its systematic business risk analysis. In conversations, both informal and formal, Negev team members draw out potential concerns and risks. Most importantly, Negev team members have experience in the drug development industry and can appropriately size up and help prioritize the risks. This applies equally to operational risks and strategic risks. Overall, Negev understands the intricacies of building out a business and is a solid partner that supports their portfolio companies through various financing stages.

Damian Kettlewell

CEO, Co-Founder & Director

CEO and Co-Founder

Ben Lightburn

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Clairvoyant Therapeutics is a Canadian biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company globally developing psilocybin therapy for the treatment of AUD.
Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose and is a pending B Corporation Certification. Clairvoyant is a member of Life Science BC and Biotechnology Innovation Organization (BIO).

As a micro-cap company in a new industry, attracting investment from Negev Capital at such an early stage helped to legitimize Psyched Wellness in the eyes of retail and institutional investors. This also validated our credibility in the perspectives of investment banks. Not only did we gain shareholders that share our vision, but we also gained partners willing to provide us with access to their vast networks and knowledge.
«y sharing our business plan with the team at Negev, we were able to work with them to identify any potential missteps in advance of implementation. This allowed us to stay on track and avoid any major setbacks. Good partners will challenge you to look beyond the spreadsheet, and that's what Negev did for us.
Psyched Wellness has successfully completed all of the scientific studies in our preclinical trial. The company is now embarking on the commercialization of Calm, our flagship product derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.

Portfolio Case Study

Chief Operating Officer, Psyched Wellness

David Shisel

Receiving the self-GRAS approval to market Calm in the USA has positioned Psyched Wellness as the first public company to bring a product derived from Amanita Muscaria to market for human consumption.
The ability to lean on the team at Negev anytime a challenge presents itself has been invaluable. The fact that we know we can reach out to them as a sounding board, as well as a check and balance of sorts, allows management to move forward more confidently. They do not try to run your business or get involved in your day-to-day operations, instead, they are on the sidelines, ready to help when you require it.
Capital is the most crucial factor for the success of a new business. The best ideas, if underfunded, may never get to market. Attracting Negev to invest in Psyched Wellness, and by extension of their investment attracting additional investors, allowed our team to focus on completing the R&D. This gave us the freedom to move towards commercialization without the constant fear of being underfunded. When the sector leaders invest in your company, others follow suit, piggybacking off of Negev's due diligence.

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

The most remarkable value that Negev Capital investment brought to our Company was the strengthening of our self-confidence. When you feel that an expert investment firm starts trusting in you, your team, your vision, your goals, your values, then your personality get stronger and what you thought at the beginning could be unachievable, now becomes achievable.
Knowledge and highly qualified professionals in the industry. We wouldn't be thinking and exploring different approaches within the industry, even going beyond mental health disorders, if it wasn't for the Negev Capital team.
Although it's a repeated sentence, I can use it with strong arguments: "the best is about to come for Biomind". Even being a young biotech company we have been taking small but firm steps with a clear and ambitious focus on becoming a pharmaceutical company, there is a lot of stigma behind psychedelic substances, and we believe that from our humble position we are helping the industry to reduce wrong interpretations about these compounds.

Portfolio Case Study

CEO of Biomind Labs

Alejandro Antalich

We are building a new concept where the power of psychedelics merge with the traditional pharma industry. It's time to make a shift in our minds, almost one eight of the global population is running out of time, "traditional", needs to be transformed to "useful", because what we really know today is that traditional antidepressants have failed. Biomind is now visible in the radars of the largest participants in the space and this is not by casualty, it's the result of hard work and a completely different approach that is bringing a huge opportunity to expand Biomind's current scope.
Leaving apart the monetary investment, the way we keep pushing every day, in a very challenging sector (science requires lot of time, same as clinical trials) where if you lack of creativity and perseverance, the chances of success are very limited, is because of someone that really understand the field, the business, the timelines and the human factor, among other variables, Negev Capital.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs' focus is to provide patients access to affordable and modern-day treatments.

Having Negev Capital as a key investor in Awakn is great, they are the ideal investor, what we call investment plus…investment plus advice and network. Negev team has always encouraged Awakn to be ambitious to have big goals….like solving Alcohol Use Disorder, but at the same time remember to focus and execute to increase probability of successful execution. Ken and his team are also supportive at opening their network to Awakn when we need answers to particular questions.

Portfolio Case Study

Negev Capital have been incredibly helpful investors from the start, making relevant introductions to collaborators, advisors, CROs, and other investors. The team at Psylo are hugely thankful for Negev's support!

Josh Ismin and Sam Banister

Co-Founders

Co-Founder & CEO

Anthony Tennyson

Awakn Life Sciences Corp. is a revenue-generating biotechnology company researching, developing, and commercialising therapeutics to treat substance and behavioral addictions. Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting 400m people globally for which the current standard of care is inadequate. Our goal is to provide effective therapeutics to addiction sufferers in desperate need and our strategy is focused on commercializing our R&D pipeline across multiple channels.

Psylo is a drug development company focused on next generation psychedelics, with a goal to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. By optimizing the pharmacology of next-generation compounds, the company produces medicines which are applicable to a broader patient population. Psylo's computational chemistry campaigns have resulted in the discovery of molecules that do not fit into any of these known categories, yet are active at 5-HT2a, 5-HT2a being the serotonin receptor that is primarily responsible for the "psychedelic effect".